Innovative Drugs Were Some Top 2020 Specialty Trends
January 1
While the COVID-19 pandemic and pharma’s efforts to counter it were the top pharma concerns in 2020, that wasn’t the only innovation within the specialty pharmacy arena. AIS Health spoke with a variety of industry experts on various trends over the past year.
What were some of the most notable developments within the specialty pharmacy industry in 2020, and why?
David Lassen, Pharm.D., chief clinical officer at Prime Therapeutics LLC: “There were many approvals for rare conditions that previously had limited or no treatment options. These include:
“Two new agents, Enspryng and Uplizna, to treat neuromyelitis optica spectrum disorder (NMOSD). These agents will compete with Soliris and off-label Rituxan and at a lower cost compared to Soliris.
Related Posts
January 12
More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
READ MORE
January 12
New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati
READ MORE
January 12
FDA Approved Four New Gene Therapies, Other Novel Agents in 2022
READ MORE
Meet Our Reporters
-
Angela Maas Managing Editor, RADAR on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and RADAR on Drug Benefits
View Leslie Small's Profile -
Lauren Flynn Kelly Managing Editor, RADAR on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Peter Johnson Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, RADAR on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Jinghong Chen's Profile -
Jill Brown Kettler Executive Editor
View Jill Brown Kettler's Profile
